drugset
drugset / Trial / NCT06160401

Evaluation of Safety, Tolerability, PK/PD, and Metabolism of Single-Dose Singletine(DC407) in Adults

NCT06160401 ↗

Phase 1 Completed 75 enrolled Guangzhou JOYO Pharma Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of Singletine in healthy adult subjects. The main questions it aims to answer are: safety and tolerability of Singletine in healthy subjects, the pharmacokinetic characteristics after single and multiple doses and the effect of food on the pharmacokinetic characteristics. Participants will be treated with Singletine orally and safety and pharmacokinetic evaluations will be conducted according to the protocol.

Timeline

Start
2020-08-18
Primary completion
2021-01-30
Completion
2021-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Singletine Unknown — Oral

Indications

No indication recorded.